Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy
1 Department of Medical Oncology, Jean Minjoz University Teaching Hospital, 3 Boulevard Alexander Fleming, Besançon F-25030, France
2 University Hospital of Besançon, Methodology and quality of life in oncology unit, Besançon, France
3 INSERM, Unit 1098, University of Franche-Comté, Besançon, Besançon, France
4 Hospital of Belfort-Montbeliard, Department of Medical Oncology, Montbeliard, France
5 Department of 344 Gastroenterology, University Hospital of Besançon, Besançon, France
6 Hospital of Vesoul, Department of Gastroenterology, Vesoul, France
7 University Hospital of Besançon, Department of Pharmacy, Besançon, France
8 EA 3181 University of Franche-Comté, Besançon, France
9 Clinical Investigational Center, CIC-1431, University Hospital of Besançon, Besançon, France
BMC Gastroenterology 2014, 14:143 doi:10.1186/1471-230X-14-143Published: 13 August 2014
Gemcitabine/Cisplatin (Gem/CDDP) combination has demonstrated a clear survival advantage over gemcitabine alone and has become a new standard in advanced Biliary Tract Carcinoma (aBTC). However, Gemcitabine/Oxaliplatin (GEMOX) combination and Gemcitabine/Carboplatin (Gem/Carb) combination regimens have shown efficacy in phase II trials and there is no comparative study between different platinum salts.
We assessed the efficacy and safety of different platinum-based chemotherapies at first line in aBTC patients. We also analysed the second-line chemotherapy.
Sixty-four consecutive patients with aBTC diagnosed between 1998 and 2010 were included for analysis. At first line chemotherapy, 44 patients received one day GEMOX regimen (gemcitabine 1000 mg/m2 and oxaliplatin 100 mg/m2 Day 1, every 2 weeks), and 20 patients received Gem/Carb regimen (gemcitabine at 1000 mg/m2 Days 1 and 8 with carboplatin delivered according to an area-under-the-curve (AUC) 5 at day 1, every 3 weeks). At second line, a total of 16 patients received a fluoropyrimidine-based chemotherapy.
With GEMOX regimen, median progression-free survival (PFS) was 3.7 months (95%CI, 2.4 to 5) and median overall survival (OS) was 10.5 months (95%CI, 6.4 to14.7). The main toxicity was peripheral neuropathy (20% grade 2 and 7% grade 3). Grade 3/4 haematological toxicities were rare.
With Gem/Carb regimen, PFS was 2.5 months (95%CI, 2.1 to 3.7) and OS was 4.8 months (95%CI, 3.7 to 5.8). The main grade 3/4 toxicities were haematological: anaemia (45%), thrombocytopenia (45%), and neutropenia (40%).
At second-line, fluoropyrimidine-based chemotherapy was feasible in only a fourth of the patients. The median OS was 5.3 months (95%CI, 4.1 to 6.6), and median PFS was 4.0 months (95%CI, 2.6 to 5.5).
One day GEMOX regimen has a favourable toxicity profile and could be an alternative to standard Gem/CDDP regimen, in particular in unfit patients for CDDP.
At second-line, selective patients may benefit from fluoropyrimidine-based chemotherapy.